Dataset opportunity
Intelligent Implants — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Intelligent Implants, usable for Diagnostic AI and Computer Vision.
Score
48
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Imaging market = $1.8 billion in 2025, CAGR 35.1%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Intelligent Implants holds a unique Medical Imaging Dataset composed of image-modality data from its SmartFuse clinical trials. This is enriched with corresponding IoT data from the implants, medical records, and event streams, providing a comprehensive, multi-modal resource perfectly suited for developing and validating high-performance Diagnostic AI models for applications like post-operative spinal fusion assessment.
This data is exceptionally valuable in the context of the global AI in Medical Imaging market, which was valued at $1.8 billion in 2025 and is projected to grow at a CAGR of 35.1% through 2033. [6] Despite access complexities due to GDPR and HIPAA regulations and shared ownership with clinical trial sites, the dataset's direct link to a specific medical device and patient outcomes offers a level of detail and rarity that is highly sought after, justifying the negotiation effort for AI developers aiming for a competitive edge. [11, 12] ⚠ Diligence (valuable data, access to negotiate): Highly sensitive medical/health data subject to GDPR and HIPAA regulations.; Data is likely tied to ongoing clinical trials (SmartFuse study).; Ownership may involve shared rights with clinical trial sites/hospitals. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence confirms Intelligent Implants holds a proprietary, multimodal dataset combining radiographic images with real-time sensor data from its SmartFuse implants. This unique collection is purpose-built for medical AI companies seeking to develop advanced diagnostic AI for orthopedics, specifically for validating and predicting bone growth and fusion success. In a global AI in Medical Imaging market projected to reach $1.8 billion by 2025, this dataset offers a rare opportunity to train algorithms on clinical study data that links imaging outcomes to continuous biological monitoring.
See dimension details ↓- Buyer Demand90
The market's explosive growth, with a projected CAGR of 35.1%, indicates intense and rising demand from AI buyers for high-quality, clinically-validated medical imaging data to build next-generation diagnostic tools. [6]
How strongly AI builders and companies are likely to want this data, based on market signals. - Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 5 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit67
⚠ review — The company's core business is selling smart medical devices that include a data/monitoring service (SmartFuse CLOUD™), making it a seller of intelligence, not a holder of dormant data. Issues: The company's product, the SmartFuse® System, is a combination of a physical implant and a cloud platform (SmartFuse CLOUD™) that provides physicians with real-; This business model of providing data and insights as part of the product offering is considered 'selling intelligence' and is an explicit exclusion criterion f; The CEO confirmed their strategy is to provide a 'smart, connected implant that provides therapeutic benefit AND remote data to support real-time clinical decis; The company is already on the market for 'smart implants', which fuse hardware with data analytics, and is not a holder of untapped data from a non-data busines
- Deep Qualification90
✓ pass — Intelligent Implants is a medical device company, not a data seller. It holds highly plausible and valuable IoT and clinical data from its SmartFuse system as a byproduct of its core activity, but this data is subject to complex ownership and strict GDPR/HIPAA regulations, making access difficult to negotiate.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
press
- “<figure><div><img src="https://imgproxy.divecdn.com/R8zOOatfqOOjEUpOxbCNlDV7PHHa3GnuaV78zH5tNcc/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9jZm9zLW9uLXRoZS1tb3ZlLmpwZWc=.webp" /></div></figure><p>Andrew Aberdale will help expand AiM’s strategic partnership ecosystem, including its recent collaboration with Siemens Healthineers, the company said.</p>”
- “<figure><div><img src="https://imgproxy.divecdn.com/tWR4JEW3Gz53IkYnMM-aUL4Q3ajMcVEQui8qDihNP2w/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5zaG90XzIwMjYtMDctMjFfYXRfMy41NC41NF9QTS5wbmc=.webp" /></div></figure><p>Multiple factors could get in the way of confirming a new commissioner before the midterm elections, experts said, leaving the agency’s long-term initiatives in limbo.</p>”
- “<figure><div><img src="https://imgproxy.divecdn.com/YluCGW2tJnVe7ms42s6iuKV0pKdWDNc01eWC5RskGgE/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HRV9IZWFsdGhjYXJlX0hRLmpwZw==.webp" /></div></figure><p>An analyst said Saccaro’s decision was “surprising,” adding that investors were not calling for his departure.</p>”
IoT / sensor data
This evidence points to proprietary time-series data generated by in-body implant sensors, offering an unprecedented ground truth on biological conditions for developing predictive AI models.
Medical records / imaging
The dataset contains radiographic images collected during formal clinical studies, providing high-value, validated visual evidence of bone growth for training diagnostic imaging algorithms.
Event streams
The holder operates a cloud platform that aggregates continuous patient data streams from implants, indicating a structured, scalable, and ongoing data collection process ideal for longitudinal AI studies.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Intelligent Implants Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market = $1.8 billion in 2025, CAGR 35.1% (source: Grand View Research). Investment score 48.0/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Hospital Engineering — Maintenance Logs Dataset Opportunity
View opportunity →healthcareJacobsbiomedical — Maintenance Logs Dataset Opportunity
View opportunity →healthcareAblemedicaldevices — Industrial Operations Dataset Opportunity
View opportunity →